Payal Goala

Dubai, DU, United Arab Emirates

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

CD28 co-stimulatory domain enhances efficacy of CER T cell therapy compared to 4-1BB in an ovarian cancer mouse model.

CD28 co-stimulatory domain enhances efficacy of CER T cell therapy compared to 4-1BB in an ovarian cancer mouse model.

Journal: Scientific reports

Published: July 21, 2025

IFN-γ-driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapy.

IFN-γ-driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapy.

Journal: The Journal of clinical investigation

Published: April 25, 2025

CAR T cell-driven induction of iNOS in tumor-associated macrophages promotes CAR T cell resistance in B cell lymphoma.

CAR T cell-driven induction of iNOS in tumor-associated macrophages promotes CAR T cell resistance in B cell lymphoma.

Journal: Research square

Published: April 16, 2025

The Th1/Th17 axis regulates chimeric antigen receptor (CAR) T cell therapy toxicities.

The Th1/Th17 axis regulates chimeric antigen receptor (CAR) T cell therapy toxicities.

Journal: bioRxiv : the preprint server for biology

Published: March 17, 2025

Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models.

Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models.

Journal: Blood cancer discovery

Published: March 10, 2025

Endogenous CD28 drives the persistent activity of CAR T cells in myeloma and lymphoma models.

Endogenous CD28 drives the persistent activity of CAR T cells in myeloma and lymphoma models.

Journal: Blood cancer discovery

Published: March 10, 2025

Sulforaphane Reverses the Expression of Various Tumor Suppressor Genes by Targeting DNMT3B and HDAC1 in Human Cervical Cancer Cells.

Sulforaphane Reverses the Expression of Various Tumor Suppressor Genes by Targeting DNMT3B and HDAC1 in Human Cervical Cancer Cells.

Journal: Evidence-based complementary and alternative medicine : eCAM

Published: March 22, 2015

Growth inhibitory and adjuvant therapeutic potential of aqueous extract of Triticum aestivum on MCF-7 and HeLa cells.

Growth inhibitory and adjuvant therapeutic potential of aqueous extract of Triticum aestivum on MCF-7 and HeLa cells.

Journal: Experimental oncology

Published: April 03, 2014

Ethanolic Neem (Azadirachta indica) Leaf Extract Prevents Growth of MCF-7 and HeLa Cells and Potentiates the Therapeutic Index of Cisplatin.

Ethanolic Neem (Azadirachta indica) Leaf Extract Prevents Growth of MCF-7 and HeLa Cells and Potentiates the Therapeutic Index of Cisplatin.

Journal: Journal of oncology

Published: September 05, 2013

Showing 1-9 of 9

Last Updated: 09/26/2026